

# L'infettivologo come riferimento tra laboratorio, specialista di reparto, farmacologo e farmacista

**Alberto Volonterio  
s.c. Malattie Infettive  
A.O. Ospedale Niguarda Ca' Granda  
Milano**

**L'inquadramento del paziente infettivo:  
non tutti i pazienti sono inquadrabili nello stesso modo**

# **...stewardship...**

- Antimicrobial stewardship includes not only limiting inappropriate use but also optimizing antimicrobial selection, dosing, route, and duration of therapy to maximize clinical cure or prevention of infection while limiting the unintended consequences, such as the emergence of resistance, adverse drug events, and cost.

# Il mondo reale: la stewardship negli Ospedali pubblici di oggi

- 6 terapie intensive
- 7 medicine
- 2 chirurgie
- Ematologia
- Oncologia
- Centro Ustioni
- Unità Spinale
- Neurochirurgia
- Neurologia
- Epatologia
- Ortopedia
- Traumatologia
- 4 Cardiologie
- Cardiochirurgia
- Chirurgia toracica
- Urologia
- Nefrologia
- Riabilitazione

E inoltre:  
Pronto Soccorso  
Microbiologia  
Farmacia  
Farmacologo clinico (se c'è)  
Direzione Sanitaria/CIO



# MA...




“...programs should be comprehensive, multidisciplinary, supported by hospital and medical staff leadership, and should employ evidence-based strategies that best fit local needs and resources...” (Ohl CA, Antimicrobial stewardship for inpatient facilities, J Hosp Med 2011 Jan;6 Suppl 1:S4-15)

# Interventi

- Consulenze per “risolvere problemi”
- Ottimizzare prescrizioni: farmaci, dosi, durate, semplificazioni.
- Creare un indirizzo terapeutico per le più comuni situazioni, ma anche
- “MODULARE LE ECCEZIONI”

“stewardship passiva e stewardship attiva”



# Esempi difficili in T.I.



- Candida score “borderline”
- Isolati addominali di germi resistenti
- Gestione di cateteri centrali e port in Ematologia
- Terapie antifungine empiriche e pre-emptive nei pazienti a rischio
- Scelte nei pazienti molto critici, emofiltrati, ustionati, obesi,multitrattati
- Malattie rare


*In generale tutto ciò che è difficilmente protocollabile è meglio sia comunque discusso e in qualche modo “centralizzato” su un referente*

# Incubi a cavallo del millennio

- MRSA, VANCO CREEP OF MRSA
- VRE
- ESBL *ENTEROBACTERIACEAE*
- CARBAPENEM- and MDR- RESISTANCE OF *P. Aeruginosa*
- KPC *ENTEROBACTERIACEAE*
- MDR ACINETOBACTER

**ESKAPE:** Enterococcus faecium (E), *S. aureus* (S), Klebsiella pneumoniae (K), Acinetobacter baumannii (A), *P. aeruginosa* (P), and *Enterobacter* spp. (E)

**ESCAPE**, *C. difficile* (C) replaces *K. pneumoniae* (K), and E now stands for *Enterobacteriaceae*, which encompasses *K. pneumoniae* and *Enterobacter* spp., as well as other critically important pathogens that can express increasing levels of antibiotic resistance (e.g., *E. coli*) (Paterson, CID 2009).



# Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship

Timothy H. Dellit,<sup>1</sup> Robert C. Owens,<sup>2</sup> John E. McGowan, Jr.,<sup>3</sup> Dale N. Gerdin,<sup>4</sup> Robert A. Weinstein,<sup>5</sup> John P. Burke,<sup>6</sup> W. Charles Huskins,<sup>7</sup> David L. Paterson,<sup>8</sup> Neil O. Fishman,<sup>9</sup> Christopher F. Carpenter,<sup>10</sup> P. J. Brennan,<sup>9</sup> Marianne Billeter,<sup>11</sup> and Thomas M. Hooton<sup>12</sup>

**Table 2. Causal associations between antimicrobial use and the emergence of antimicrobial resistance.**

- 
- Changes in antimicrobial use are paralleled by changes in the prevalence of resistance.
  - Antimicrobial resistance is more prevalent in health care-associated bacterial infections, compared with those from community-acquired infections.
  - Patients with health care-associated infections caused by resistant strains are more likely than control patients to have received prior antimicrobials.
  - Areas within hospitals that have the highest rates of antimicrobial resistance also have the highest rates of antimicrobial use.
  - Increasing duration of patient exposure to antimicrobials increases the likelihood of colonization with resistant organisms.

# **Interventions to improve antibiotic prescribing practices for hospital inpatients (Review)**

**Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, Ramsay CR, Wiffen PJ, Wilcox M**

The Cochrane Library, april 30 2013

the challenge to reduce inappropriate antibiotic prescribing, the implication being that antibiotic resistance is largely a consequence of the selective pressures of antibiotic usage and that reducing these pressures by the judicious administration of antibiotics will facilitate a return of susceptible bacteria or, at least, will prevent or slow the pace of the emergence of resistant strains.

sepsis kills more people annually than myocardial infarction or breast, colon and lung cancer combined ([\*Robson 2008\*](#)), and delay in effective antibiotic treatment is associated with increased mortality ([\*Daniels 2010\*](#); [\*Kumar 2006\*](#)).

**The term 'antibiotic stewardship' is used to capture the twin aims of ensuring effective treatment of patients with infection and minimizing collateral damage from antimicrobial use**

# Carbapenem-Resistant *Enterobacteriaceae*: Epidemiology and Prevention

Neil Gupta,<sup>1,2</sup> Brandi M. Limbago,<sup>2</sup> Jean B. Patel,<sup>2</sup> and Alexander J. Kallen<sup>2</sup>

<sup>1</sup>Epidemic Intelligence Service and <sup>2</sup>Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia



KPC



NDM

...globalizing...




### Percentage resistance

- < 1%
- 1 to < 5%
- 5 to < 10%
- 10 to < 25%
- 25 to < 50%
- ≥ 50%
- No data reported or less than 10 isolates
- Not included



Proportion of Carbapenem  
Resistant (R+I) *Klebsiella*  
*pneumoniae* Isolates in  
Participating Countries in  
2009




**Percentage resistance**

- █ < 1%
- █ 1 to < 5%
- █ 5 to < 10%
- █ 10 to < 25%
- █ 25 to < 50%
- █ ≥ 50%
- No data reported or less than 10 isolates
- Not included




Proportion of Carbapenem  
Resistant (R+I) *Klebsiella*  
*pneumoniae* Isolates in  
Participating Countries in  
**2010**



- █ Liechtenstein
- █ Luxembourg
- █ Malta

# Carbapenemase-producing *Enterobacteriaceae* in Europe



# KPC-producing *K. pneumoniae* – the Italian epidemics



**late 2008**

**The first reported  
cases of KPC-Kp**

**ST258**

Giani et al – JCM 2009



**early 2011**

**ST258, ST512 (CC258)**

- Fontana et al – BMC Res Notes 2010
- Marchese et al – J Chemother 2010
- Ambretti et al – New Microb 2010
- Gaibani et al – Eurosurg 2011
- Mezzatesta et al – CMI 2011
- Agodi et al – JCM 2011
- Richter et al – JCM 2011
- Di Carlo et al – BMC Gastroent 2011



**late 2012**


**ST512  
ST258**

**ST101  
ST15  
ST147-like**

AMCLI – CoSA CRE network  
Frasson et al – JCM 2012

**Percentage resistance**

- < 1%
- 1 to < 5%
- 5 to < 10%
- 10 to < 25%
- 25 to < 50%
- ≥ 50%
- No data reported or less than 10 isolates
- Not included



# Interventi di contenimento per le enterobatteriacee carbapenemasi-produttrici




©Ron Leishman \* illustrationsOf.com/5858

# Stewardship interventions

- Increase effective prescribing
- Decrease excessive prescribing
- Review and make change
- Decrease targeted antibiotics
- Decrease colonisation and infection CD
- Decrease colonisation and infection MDR
- Decrease costs and improve savings
- Improve clinical outcome
- Decrease mortality

# Persuasive interventions:

- Dissemination of educational materials in printed form or via educational meetings;
- Reminders;
- Audit and feedback;
- Educational outreach (academic detailing or review and recommend change).



**Restrictive interventions (a change to the antibiotic formulary or policy implemented through an organizational change that restricts the freedom of prescribers to select some antibiotics).**




1. **Compulsory order form** - prescribers had to complete a form with clinical details to justify use of the restricted antibiotics;
2. **Expert approval** - the prescription for a restricted antibiotic had to be approved by an Infection specialist or by the Head of Department;
3. **Restriction by removal** - a restrictive policy was imposed in target wards, units or operating theatres, for example by removing restricted antibiotics from drug cupboards;
4. **Review and make change** - the difference between this intervention and review and recommend change (educational outreach) is that the reviewer changed the prescription rather than giving health professionals either a verbal or written recommendation that they should change the prescription.

In addition some studies included **automatic stop orders**.



- The results show that interventions to reduce excessive antibiotic prescribing to hospital inpatients **can reduce antimicrobial resistance or hospital-acquired infections**, and interventions to increase effective prescribing **can improve clinical outcome**. This update provides more evidence about unintended clinical consequences of interventions and about the effect of interventions to reduce exposure of patients to antibiotics. The meta-analysis supports the **use of restrictive interventions when the need is urgent, but suggests that persuasive and restrictive interventions are equally effective after six months.**





**Figure 3.** Meta-regression of the difference in effect size between restrictive and persuasive interventions at 1, 6, 12 and 24 months after the intervention. The difference is Restrictive minus Persuasive so positive values for the difference indicate greater effect size for Restrictive interventions and negative values indicate greater effect size for Persuasive interventions. The bars show 95% CI for the mean difference

# Misure amministrative

- Restrizioni somministrative
- Preautorizzazioni
- Fogli somministrativi
- Educazione
- CIO: implementazione
- Istruzione di audit

**MODULO  
RICHiesta  
COLISTINA**

**Esempio: SCHEDA  
DI PRESCRIZIONE**



U.O.....

Data della richiesta ..../..../.....

CODICE

**PAZIENTE**

Data inizio terapia ..../..../.....

Richiesta per: ↑ Inizio Terapia

↑ Prosecuzione Terapia

Durata prevista terapia.....giorni

DOSE RICHIESTA: \_\_\_\_\_ mg x \_\_\_\_\_ die ↑ per aerosol ↑ per ev

Status del paziente: ↑ Shock Settico ↑ Sepsis Grave ↑ Sepsis (vedi definizioni allegate)

Motivazione della Richiesta :

↑ Terapia empirica per sospetta infezione : ↑ Sepsis grave ↑ Shock settico

Sede: ↑ Sangue (Cuore e vasi ) ↑ SNC ↑ Apparato respiratorio ↑ Addome ↑ Corte e annessi ↑ altro

Precedente isolamento di germe Gram – multi resistente: No ↑ Si ↑ (allegare antibiogramma): data \_\_\_\_\_ materiale ↑

Tampone cutaneo ↑ Tampone orofaringeo ↑ Urina ↑ Basse vie respiratorie ↑ Tampone rettale/feci

Ricerche batteriologiche in corso: ↑ Nessuna

↑ Coltura → ↑ Sangue ↑ Liquor ↑ Pus ↑ Urina ↑ Basse vie respiratorie

↑ altro .....

↑ Terapia mirata per isolamento di (battere/i) .....

.....) da ↑ Sangue ↑ Liquor ↑ Pus ↑ Basse vie respiratorie in data ...../...../.....

(allegare antibiogramma)

↑ Insuccesso precedente terapia con .....

dal ..../..../.... al ..../..../.... Note.....

.....  
Richiesto Parere dell'Infettivologo Dr. ....

↑ NO

↑ SI

↑ In attesa

Spazio riservato alla FARMACIA

Farmaco consegnato ..... Quantità ..... Data ..../..../....

Il Farmacista .....

*Timbro*  
*Firma del Medico*


# Misure mediche

- “Cycling”
- Ottimizzazione delle dosi
- De-escalation e conversione a terapie per os
- Limitazione di antibiotici
- Limitazione delle terapie di combinazione
- Implementazione di linee-guida e orientamenti terapeutici

## Is Antibiotic Cycling the Answer to Preventing the Emergence of Bacterial Resistance in the Intensive Care Unit?

Probably not

1. Antibiotic cycling or antibiotic rotation: A fixed temporal pattern for the predominant use of an antibiotic class or classes, followed by their repeated removal and reintroduction over time.



2. Scheduled antibiotic changes: A predetermined and scheduled change in the predominant antimicrobial agent employed. Changes in the antibiotic classes employed are often based on changing patterns of antimicrobial sensitivities and are not simply time based.




3. Antibiotic mixing: A strategy whereby all or most available antimicrobial classes are employed to minimize undue pressure for the emergence of resistance from having a single or limited number of antibiotic classes available.



Review

## Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock - does the dose matter?

Federico Pea<sup>1</sup> and Pierluigi Viale<sup>2</sup>




The antimicrobial therapy puzzle. MIC, minimum inhibitory concentration. Reproduced with permission from Pea and Viale [5].

# Sources of variability in pharmacology

## Pharmacological variability depending on :

- PATIENT**
- Aged
  - Children
  - Male or female
  - Female:
    - Menstrual cycle
    - Pregnancy
    - Suckling



- DRUG:** galenic
- Immediate release
  - Sustained release

- DRUG:**
- Route of administration
- Oral: fasting
  - Cutaneous: patches

- PATHOLOGY**
- Renal failure
  - Hepatic failure
  - Cardiac failure
  - Immunodépression
  - Dénutrition
  - Obesity

- DRUG:**
- Conditions of administration
- Single dose
  - Repeated doses
  - Constant rate infusion

# **TERAPIA ANTIBIOTICA EMPIRICA NELLA SEPSI GRAVE SHOCK SETTICO**

## **Criteri di base**

- **Entro la prima ora**
- **Ampio spettro**
- **Dose di carico indipendente dalla creatinina clearance**
- **De-escalation e rivalutazione dose e spettro terapia a 24, 48 e 72 h\* con emocolture , gram su campioni biologici, creatinina clearance, Ag urinari → consulenza infettivologica, TDM**
- **Considerare diffusione nel sito d'infezione**
- **Considerare sempre focolai eradicabili**
- **Consultare specialista (ematologo, oncologo, infettivologo) se casi complessi o paz. immunodepressi**

# Terapia antibiotica empirica nella sepsi grave- shock settico

Tabella riassuntiva

Sito d'infezione	Caratteristiche epidemiologiche	Terapia
Sede ignota	ESBL-	Piperacillina Tazobactam + <b>Vancomicina</b>
	ESBL+	Meropenem + <b>Vancomicina</b>
Polmonite	Comunitaria	Rocefin+ <b>Levofloxacina/Azitromicina</b>
	Nosocomiale o Alto Rischio	Meropenem + <b>Levofloxacina</b> ± <b>Vancomicina</b>
IAI	Di comunità rischio ESBL-	Piperacillina Tazobactam
	Di comunità rischio ESBL +	Meropenem
	Nosocomiale	Meropenem + <b>Vancomicina</b> + <b>Echinocandina*</b>
SSTI	Non Fournier	Daptomicina* + <b>Meropenem</b> + <b>Rifampicina</b>
	Fournier	Daptomicina + <b>Meropenem</b> + <b>Echinocandina</b>
Urosepsi	ESBL-	Piperacillina/tazobactam
	ESBL+	Meropenem

\* Da richiedere con consulenza infettivologica

# **What is the optimal duration of antibiotic therapy?**

## **John Paul**

antibiotics may be associated with adverse reactions, and prolonged exposure to antibiotics, may encourage the development or acquisition of antibiotic resistant organisms. Also, antibiotic treatment is expensive and problems may occur with compliance.

Comparative outcome studies provide a solution but require large numbers to provide the statistical power for significance. Pooling of multiple studies may be affected by inconsistencies in study design but may still yield clues...

When optimising therapy for an infection, a lot of variables have to be juggled, including choice of antibiotic, the patient's immune status, the infecting agent, and the nature of the septic focus...

# **Antimicrobial stewardship: a matter of process or outcome?**


Khadem TM, Dodds Ashley E, Wrobel MJ, Brown

- **Process measures** have been validated and can evaluate quality of care; however, they do not adequately describe the clinical impact of these programs at the patient level. **Outcome measures** also have limitations; they are not a direct measure of quality of care. Therefore, **both process and outcome measures need to be defined and assessed when evaluating an ASP to confirm that goals of the intervention are attained and clinical objectives are met.**
- Most available well-designed studies judging the effectiveness of ASPs use process measures alone. Adding improvements in clinical outcomes to process measures would theoretically attract the attention of a broader audience and provide additional support to expand current ASPs and develop novel ASPs

## Antimicrobial stewardship: bridging the gap between quality care and cost

Debra A. Goff

Figure 1 Projected cost savings if antimicrobial-resistant infection rates were reduced from 13.5 to 10%




"estimated cost of MDR in USA, 2005: 5billions\$


# Qualities for a stewardship: le malattie infettive e il futuro...



brillantezza



riflessione



dynamismo



Un esperto di antibiotici



aggressività



persuasione



E un ottimismo quasi infantile



Grazie dell' attenzione